The Therapeutics Initiative's objectives are unbiased review and dissemination of therapeutic evidence. Our recommendations are intended to apply to most patients; exceptional patients require exceptional approaches. We are committed to evaluate the effectiveness of our educational activities using the Pharmacare/PharmaNet databases without identifying individual physicians, pharmacies or patients. The Therapeutics Initiative is funded through a 5-year grant to the University of British Columbia from the Government of British Columbia, Ministry of Health and Ministry Responsible for Seniors.

Therapeutics Letter, issue 26, September - October 1998


  • Donepezil (Aricept®)
  • Levofloxacin (Levaquin®)
  • Pantoprazole (Pantoloc®)
  • Quetiapine (Seroquel®)

  • Donepezil (Aricept®)

    Levofloxacin (Levaquin®)

    Levofloxacin is a fluoroquinolone antibiotic, which is the levo-rotatory stereoisomer of ofloxacin (Floxin®). Antibacterial activity resides predominantly in the levo-rotatory isomer, but levofloxacin kinetics are similar to ofloxacin.(4)

    Pantoprazole (Pantoloc®)

    Quetiapine (Seroquel®)

    This Therapeutics Letter contains an assessment and synthesis of published (and whenever possible peer-reviewed) publications up to October 1,1998. We attempt to maintain the accuracy of the information contained in the Therapeutics Letter by extensive literature searches and verification by both the authors and the editorial board. In addition this Therapeutics Letter was submitted for review to 78 experts and primary care physicians in order to correct any identified shortcomings or inaccuracies and to ensure that the information is concise and relevant to clinicians.


    1. Rogers SL, Friedhoff LT. The Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease: Results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. Dementia 1996; 7:293-303.
    2. Rogers SL, Farlow,MR, et al. A 24-week, double-blind, placebo controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50:136-145.
    3. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998;138:1021-1031.
    4. M. Verho et al. Pharmacokinetics of levofloxacin in comparison to the racemic mixture of ofloxacin in man. Drug Metabolism and Drug Interactions 1996: 13: 57-67.
    5. Mossner J. Holscher AH, Herz R, Schneider A. A double-blind study of pantoprazole and omeprazole in the treatment of reflux esophagitis: a multicentre trial. Aliment Pharmacol Ther 1995;9:321-6.
    6. Corinaldesi R, Valentini M, Belaiche J, Colin R, Geldof H, Maier C. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Aliment Pharmacol Ther 1995;9:667-71
    7. Rehner M, Rohner HG, Schepp W. Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration - A multicentre study. Aliment Pharmacol Ther 1995;9:411-416.
    8. Adamek RJ, Szymanski C, Pfaffenbach B. Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. pylori infection. Am J Gastroenterol 1997;92:1949-1950.
    9. Jaspersen D. Diehl KL, Schoeppner H, Geyer P, Martens E. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. Alim Pharm and Ther 1998;12:49-52.
    10. Arvanitis LA, Miller BG, Borison RL, Pitts WM, Sharif ZA, Hammer MB, Shriqui CL, Williams R, Daniel DG, Shehi GM, Patterson WM, Merideth CH. Multiple fixed doses of 'seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biological Psychiatry 1997;42: 233-246.
    11. Peuskens J. Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatrica Scandinavica. 96(4):265-273, 1997 Oct.
    12. King DJ, Link CJ, Kowalcyk B. A comparison of BID and TID dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology 1998; 137(2):139-46.

    Please send feedback!

    Back to Therapeutics Letter.

    Back to the Therapeutics Initiative Home Page.

    ©Therapeutics Initiative. Last updated: November 6, 1998.